BioSpace News Archive

Cellectis today publishes an article in Cancer Immunology Research demonstrating pre-clinical proof-of-concept data of UCART20x22 product candidate, Cellectis’ first allogeneic dual CAR T-cell targeting the CD20 and CD22 antigens.

Enliven Therapeutics, Inc., a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, announced that management will present at the following investor conferences in June.

Adicet Bio, Inc., a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, announced it granted inducement awards on May 31, 2023.

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that Dr. James Breitmeyer, Oncternal’s President and Chief Executive Officer will present at the 2023 Jefferies Healthcare Conference.

Universal Health Services, Inc. (NYSE: UHS) announced today that Steve Filton, Executive Vice President and Chief Financial Officer will participate in a fireside chat at the 44th Annual Goldman Sachs Global Healthcare Conference on Monday, June 12, 2023, at 4:40pm (PT)/7:40pm (ET).

Telesis Bio Inc. announced it has signed a securities purchase agreement with a syndicate of healthcare-focused institutional investors that have agreed to provide initial upfront funding of $28.0 million in gross proceeds to Telesis Bio through a private placement of redeemable convertible preferred stock.

ByoPlanet, a wholly owned subsidiary of Plandai Biotechnology, Inc., a leading innovator in revolutionary cleaning technology, announced the completion of a third-party valuation firm’s estimates of ByoPlanet’s business and assets based on ByoPlanet’s unaudited financial statements and internal projections.

BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its subsidiary, BioSyent Pharma Inc., has received regulatory approval from Health Canada for a new oncology supportive care product.

Santhera Pharmaceuticals announces the publication of its Annual Report 2022 with fully audited results for the year ended December 31, 2022.

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO™ (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F (RSVpreF) vaccine, for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years and older.